Compare · AZN vs LGVN
AZN vs LGVN
Side-by-side comparison of AstraZeneca PLC (AZN) and Longeveron Inc. (LGVN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and LGVN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $255.09B, about 12973.1x LGVN ($19.7M).
- Over the past year, AZN is down 12.6% and LGVN is down 57.5% - AZN leads by 44.8 points.
- Both names hit the wire about 15 times in the past 4 weeks.
- AZN has more recent analyst coverage (25 ratings vs 2 for LGVN).
- Company
- AstraZeneca PLC
- Longeveron Inc.
- Price
- $164.47-3.04%
- $0.62-2.27%
- Market cap
- $255.09B
- $19.7M
- 1M return
- -9.74%
- -19.38%
- 1Y return
- -12.65%
- -57.47%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2021
- News (4w)
- 15
- 15
- Recent ratings
- 25
- 2
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Longeveron Inc.
Longeveron Inc., a clinical stage biotechnology company, engages in developing cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications comprising aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- AstraZeneca downgraded by HSBC Securities
- SEC Form 6-K filed by AstraZeneca PLC
- Officer Sharma Mani was granted 2 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,265 units (SEC Form 4)
- The Quantum Sector Hits an Inflection Point: Federal Money, Real Milestones, and a Security Race Running in Parallel
- Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 11-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
Latest LGVN
- New insider Desai Arjun Jj claimed no ownership of stock in the company (SEC Form 3)
- Longeveron Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- New insider Ascheim Deborah claimed no ownership of stock in the company (SEC Form 3)
- New insider Cann Leah Rush claimed no ownership of stock in the company (SEC Form 3)
- Longeveron Announces Presentation of Clinical Data at the 2026 Alzheimer’s Association International Conference (AAIC) that Indicate Its Cellular Therapy Laromestrocel Reduced Neuroinflammation in Patients with Alzheimer’s Disease
- SEC Form S-8 filed by Longeveron Inc.
- Chief Scientific Officer Hare Joshua was granted 600,000 units of Class B Common Stock, increasing direct ownership by 83% to 1,321,796 units (SEC Form 4)
- Longeveron Inc. filed SEC Form 8-K: Leadership Update
- Chief Executive Officer Willard Stephen H covered exercise/tax liability with 18,046 shares, decreasing direct ownership by 2% to 771,681 units (SEC Form 4) (tax liability)
- Chief Financial Officer Locklear Lisa covered exercise/tax liability with 22,505 shares, decreasing direct ownership by 5% to 443,181 units (SEC Form 4) to satisfy tax liability